- Home
- IMMX vs CCEL Comparison
IMMX vs CCEL Comparison
Compare IMMX & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- CCEL
- Stock Information
- Founded
- IMMX 2014
- CCEL 1989
- Country
- IMMX United States
- CCEL United States
- Employees
- IMMX N/A
- CCEL N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- CCEL Managed Health Care
- Sector
- IMMX Health Care
- CCEL Health Care
- Exchange
- IMMX Nasdaq
- CCEL Nasdaq
- Market Cap
- IMMX 50.1M
- CCEL 51.9M
- IPO Year
- IMMX 2021
- CCEL 1997
- Fundamental
- Price
- IMMX $2.09
- CCEL $5.05
- Analyst Decision
- IMMX Strong Buy
- CCEL Strong Buy
- Analyst Count
- IMMX 1
- CCEL 1
- Target Price
- IMMX $7.00
- CCEL $8.50
- AVG Volume (30 Days)
- IMMX 59.6K
- CCEL 10.1K
- Earning Date
- IMMX 05-20-2025
- CCEL 04-15-2025
- Dividend Yield
- IMMX N/A
- CCEL 4.96%
- EPS Growth
- IMMX N/A
- CCEL N/A
- EPS
- IMMX N/A
- CCEL 0.01
- Revenue
- IMMX N/A
- CCEL $32,102,750.00
- Revenue This Year
- IMMX N/A
- CCEL $2.49
- Revenue Next Year
- IMMX N/A
- CCEL $0.95
- P/E Ratio
- IMMX N/A
- CCEL $316.80
- Revenue Growth
- IMMX N/A
- CCEL 2.33
- 52 Week Low
- IMMX $1.26
- CCEL $4.75
- 52 Week High
- IMMX $2.71
- CCEL $9.50
- Technical
- Relative Strength Index (RSI)
- IMMX 61.41
- CCEL 38.04
- Support Level
- IMMX $1.92
- CCEL $4.80
- Resistance Level
- IMMX $2.25
- CCEL $5.10
- Average True Range (ATR)
- IMMX 0.17
- CCEL 0.29
- MACD
- IMMX 0.03
- CCEL -0.00
- Stochastic Oscillator
- IMMX 67.61
- CCEL 25.00
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.